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ABSTRACT
Objective: The objective was to study the adverse drug reactions (ADRs) associated with first-line anti-tubercular drugs for clinical presentations, 
causality, and severity.
Methods: A retrospective study was undertaken in a 750 bedded tertiary care teaching hospital of central India for the duration of 1 year 
(May 2013-May 2014). Patients diagnosed with tuberculosis and under treatment with the first-line anti-tubercular drugs were study subjects. 
Causality, preventability, and severity were analyzed and other parameters such as male to female ratio, most affected system, most common class of 
drug, and common types of ADRs, were studied.
Results: Nearly 118 patients were started on anti-tubercular treatment of first-line drugs in the study duration. Out of these 45 patients suffered 
one or more ADRs with a total number of reported ADRs being 91. 57.77% were males. Maximum patients belonged to the age group of 31-40 years 
(26.66%). The most commonly involved system was hepatic and biliary system (53.33%) followed by gastrointestinal system (51.11%), the most 
common ADR observed was disturbed liver transaminases (33.33%) followed by nausea and vomiting (28.88%). Causality assessment by Naranjo’s 
scale showed 58.2% ADRs scoring probable, 31.86% were of possible score, whereas 9.8% definite score category. Severity assessment shows 68.88% 
cases of mild grading, 31.11% of moderate and no case of severe grading was reported in the study duration.
Conclusions: Vigilance regarding these ADRs occurrences can result in early diagnosis and thus, proper management can be instituted earliest. This 
will build confidence of patients and will decrease the dropouts which in turn can result in decrease chances of developing drug-resistant strains.
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INTRODUCTION
Morbidity, mortality, social issues, and dual infections like HIV may 
complicate the overall picture of tuberculosis (TB). For a developing 
country like India, it not only affects the physical health status but puts 
forth the financial constraint on health sector.
TB remains one of the major health problems in our country, and 
it kills more adults than any other infectious disease. In India, about 
1.8 million new cases of TB are detected every year, of which one-fifth 
are extra-pulmonary TB cases [1,2]. An adverse drug reaction (ADR) 
has been defined as any noxious, unintended, and undesired effect of a 
drug which occurs at a dose used in humans for prophylaxis, diagnosis, 
therapy or modification of physiological functions [11].
High incidence of infection has caused a large number of morbidity and 
mortality which is partly due to serious adverse reactions induced by 
anti-TB drugs [3,4]. In 1982, the Revised National TB Control Program 
(RNTCP) reviewed the National TB control program and concluded 
that it suffered from managerial weakness, inadequate funding, an 
over-reliance on X-rays, nonstandard treatment regimens, low rates 
of completion of treatment and a lack of systematic information on 
treatment outcome [5,6].
Following their commendations of an expert committee, a revised 
strategy to control TB was tested in 1993 and the RNTCP was started 
in 1997, and geographic coverage of more than 97% was achieved by 
the end of 2005 [7]. Directly observed treatment, short course (DOTS) 
was introduced in India in 1993 as part of RNTCP. The standard anti-
TB short course chemotherapy regimen, which comprised of taking 
drug combinations of isoniazid, rifampicin, pyrazinamide, ethambutol, 
and/or streptomycin for 6-9 months. The WHO recommended treatment 
strategy for detection and cure of TB is DOTS, which is the most effective 
strategy available for controlling the TB epidemic today [8]. Treatment of 
TB has been revised with time and is treated using the DOTS and revised 
national TB program. Pharmacotherapy of TB consists of giving drug 
combinations to increase the effectiveness and decrease the emergence 
of drug resistance. But more the number of drugs, adverse effects are 
added up too. High incidence of infection has caused a large number of 
morbidity and mortality which is partly due to serious adverse reactions 
induced by anti-TB drugs [3,4]. Central India carries a burden of this 
problem to the extent to share a decent percentage of reported cases.
Incidence of ADR being high with these drugs is resulting in more 
dropouts, change of regime and inadequate or incomplete treatment, 
all these contributing to emergence of multidrug resistant (MDR) and 
extensively drug-resistant cases (XDR) strains increasing the morbidity 
and mortality. This study is being carried out to estimate the burden 
of problem in our hospital so that clear picture can be obtained and 
physician be oriented more to provide counseling and also diagnose 
these ADRs as soon as possible as early management improves the 
outcome. Furthermore, ADR reporting practice was stressed upon 
during collection of data.
Objectives
To analyze and assess ADRs induced by anti-TB drugs by analyzing 
the case sheets for studying adverse drug events, common ADRs, 
common drugs accounting for ADRs, systems involvement, causality 
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assessment (assessed by Naranjo’s algorithmic scale) [9], Severity of 
ADRs (modified Hartwig and Siegel Scale) [10].
MATERIALS AND METHODS
A retrospective study was undertaken in a tertiary care teaching hospital. 
Data were collected from the medical record section and department of 
TB and chest by reviewing patient’s files. Data were analyzed for the ADRs 
that occurred in the specified period of 1 year (1st May 2013-1st May 2014). 
Study protocol was approved by institutional ethics committee. Discretion 
of information acquired was secured, and all the measures to maintain the 
confidentiality were undertaken, during the study. Suitable study design 
for ADR profile study was developed for compiling the data. Inclusion 
criteria consisted of all patients of either gender.
The patients diagnosed with pulmonary TB and on treatment under 
DOTS regimen were included in the study. These patients were on anti-
TB drugs, a combination of four first-line drugs (isoniazid, rifampin, 
pyrazinamide and ethambutol). Patients of hepatic dysfunction were 
excluded from the study.
Any ADR marked by consultant physician based on clinical findings, 
laboratory tests and medical records were included in the study. All the 
results were calculated in percentages and proportions. Common ADRs, 
common drugs accounting for ADRs, systems involvement, causality 
assessment (assessed by Naranjo’s algorithmic scale) [9], Severity of 
ADRs (Modified Hartwig and Siegel Scale) [10] were studied. Causality 
which was assessed by Naranjo’s algorithmic scale [9] is the most 
common assessment tool of ADR, and verifies the chances of whether 
an ADR is essentially due to the drug or it is the result of other causes, 
the likelihood is consigned by the score, termed as definite, probable or 
possible [9]. Severity of ADR (assessed by Modified Hartwig and Siegel 
Scale) [10]. Examples of ADRs assessed as severe are those that caused 
the death, directly life-threatening, lengthened hospitalization, or shift 
to a higher level of clinical care [10].
RESULTS
In the study duration, 118 patients were started on anti-tubercular 
treatment (ATT) of first-line drugs. Of these 45 patients suffered one 
or more ADRs with a total number of reported ADRs being 91. Of 
45 patients, 26 cases (57.77%) were males, and 19 cases (42.22%) were 
females. Maximum patients belonged to the age group of 31-40 years 
(26.66%) followed by 21-30 years (22.22%) and 11-20 years (17.7%) 
(Fig. 1).
The most commonly involved system was hepatic and biliary system 
(53.33%) followed by gastrointestinal (GI) system (51.11%), 
dermatological (28.88%) CNS and PNS (22.22%), fever and flu-like 
syndrome (13.33%), optic neuritis and blurred vision (11.11%) & 
metabolic system (11.11%), renal toxicity (4.44%), gout and arthralgia 
(4.44%), hematological toxicities (2.22%) (Fig. 2).
The most common ADR observed was disturbed liver transaminases 
(33.33%) followed by nausea and vomiting (28.88%). Other types of 
ADRs that were seen included 20% cases of hepatitis, headache, and 
rash each. Constipation and fever and flu-like syndrome accounted 
for about 13.33% each. Blurred vision and optic neuritis (11.11%), 
metabolic disturbances including hyperglycemia (11.11%) were also 
recorded. Diarrhea was reported in 8.88% patients.
Other ADRs also included peripheral neuritis (4.44%), arthralgia 
and with increased blood uric acid level (4.44%), pruritis (4.44%), 
peripheral neuritis (4.44%), increased blood urea (2.22%), and urinary 
complaints like dysuria (2.22%) (Fig. 3).
Causality assessment (Naranjo’s scale)
Nearly 45 cases of ADRs were analyzed in which about 91 ADRs were 
reported. After assessment, 58.2% scored probable, 31.86% were of 
possible score, whereas 9.8% were in definite score category (Fig. 4).
Severity assessment using modified Hartwig and Siegel scale
Assessment shows 68.88% cases of mild grading, 31.11% of moderate, 
and no case of severe grading were reported in the study duration 
(Fig. 5).
DISCUSSION
TB is posing a major hazard to the health authorities and the medical 
fraternity by emerging as a serious problem causing high morbidity and 
mortality rates. Its association with HIV infection and drug resistance 
causing MDR-TB and XDR-TB is making this disease difficult to treat 
day by day. ADR associated with these drugs further complicates the 
picture. ADRs resulting in dropouts, insufficient treatment, and cost of 
treating ADRs are an essential component and have to be addressed. 
In a study conducted in Iranian population hospitalized in the general 
ward, ADR has been reported as the cause of admission for 8% of 
patients [12]. In another study conducted for detecting anti-infectives 
induced adverse reactions in Iranian hospitalized patients, the total rate 
of hospitalization because of an ADR was estimated as 2.2% [13]. This 
shows the high incidence of ADRs with anti-tubercular drugs. In our 
study also, many ADRs were reported which needed hospitalization like 
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fever in some patients also needed inpatient care. It has been estimated 
that 10-20% of isoniazid recipients develop elevated liver enzymes [19]. 
In our study, incidence in males was found to be high about 58%. It may 
be due to the fact that the males are having higher risk factors like 
smoking, alcoholism, and drug addiction to get TB than females and 
men are socially more active and visit public places more often. These 
risks make them more vulnerable for TB infection [14]. Though there 
are studies which have found the incidence to be higher in females. They 
suggest females are at higher risk of developing ADRs [20]. It might 
be because they pass through life stages like pregnancy, menarche, 
etc., which modify the drug response [21]. Studies from the UK and 
Canada also reported females to have a significantly higher incidence 
of ADRs due to ATT drugs [22]. In our study, the highest percentage of 
patients was found in the age group 31-40 years about 27% followed 
by 21-30 years of age group (22%). Edoh and Adjei, also found a higher 
incidence of TB in the age group of 21-40 years with the highest peak 
of 29.7% in the group of 31-40 years [15]. This is probably because 
the people in this age group are involved in TB infectious activities 
like smoking, alcohol intake, etc., which results in the weakening of 
immunity [16]. Immunity plays a major role in the pathogenesis and 
manifestations of the disease.
The major ADR burden is borne by liver and GI tract. Hepatotoxicities 
share the major percentage of ADR profile of these drugs. 
Hepatotoxicities are major adverse effects of all three main anti-TB 
drugs, isoniazid, rifampin, and pyrazinamide. In our study, the most 
commonly involved system was hepatic and biliary system (53.33%) 
followed by GI system (51.11%) with nausea vomiting in about 29% 
cases, constipation in about 13.33% cases whereas, diarrhea was 
reported in 8.88% cases., In 2012, Shinde et al. reported 12.65% of GI 
upset cases and 6.27% of hepatotoxicity cases caused by first-line anti-
TB agents [17]. Khalili et al. reported that ADR including hepatotoxicity 
can be one of the main reasons for poor adherence, and it will result in 
interruption and change in the treatment [18]. Treatment interruption 
or change of drugs both can result in inadequate or improper treatment 
and can further affect the course of the disease and may also result in 
the emergence of drug-resistant strains which can further limit the 
options. Other types of ADRs that were seen included hepatitis (20%), 
headache (20%), and rash in also about 20% patients. Fever flu-like 
syndrome accounted for about 13.33%. Blurred vision and optic neuritis 
(11.11%), metabolic disturbances including hyperglycemia were seen 
in about 11.11% patients. Other ADRs also included peripheral neuritis 
(4.44%), arthralgia, and with increased blood uric acid level (4.44%), 
pruritis (4.44%), peripheral neuritis (4.44%), increased blood urea 
(2.22%), and urinary complaints like dysuria (2.22%).
Causality assessment was done using Naranjo’s scale. All 45 cases of 
ADRs were analyzed in which about 91 ADRs were reported. After 
assessment, 58.2% scored probable, 31.86% were of possible score, 
whereas 9.8% were in definite score category. Severity assessment 
using modified Hartwig and Siegel scale showed 68.88% cases of mild 
grading, 31.11% of moderate and no case of severe grading. A study by 
Sivaraj, et al. RNTCP regimens with and without DOTS, also reported 
the majority of reactions to be mild (68.97%).
CONCLUSION
Anti-tubercular drugs may cause high incidences of ADRs ranging 
from mild to severe. This can cause not only significant morbidity or 
mortality; cost of treating them can also increase the burden on our 
health resources. MDR-TB and XDR-TB are not only difficult to treat with 
limited options, second-line drugs have more toxicities and treatment 
being a lot more expensive than the first-line drugs with effectiveness 
reported to be lower. Vigilance regarding these ADRs occurrences can 
result in early diagnosis and thus, proper management can be instituted 
earliest. This will build confidence of patients and will decrease the 
dropouts which in turn can result in decrease chances of developing 
drug-resistant strains.
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